VCG
ENTA icon

Vantage Consulting Group’s Enanta Pharmaceuticals ENTA Stock Holding History

Vantage Consulting Group’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-532
Closed -$22K – 544
2020
Q4 		$22K Buy
+532
New +$23.4K ﹤0.01% 834

Other funds holding ENTA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vantage Consulting Group's ENTA Position: Q1 2021 in Review

Vantage Consulting Group sold out of Enanta Pharmaceuticals (ENTA) in Q1 2021, closing a stake of 532 shares — an estimated $22K sold.

Vantage Consulting Group first reported a position in ENTA in Q4 2020 and held it in 1 quarter. The position peaked at $22K in Q4 2020. 148 funds tracked by Wall St. Rank hold ENTA as of Q1 2021.

  • Vantage Consulting Group reported no remaining Enanta Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Vantage Consulting Group sold 532 Enanta Pharmaceuticals shares in Q1 2021, an estimated $22K.
  • Vantage Consulting Group first reported a position in Enanta Pharmaceuticals in Q4 2020 and held it in 1 quarter.
  • Vantage Consulting Group's Enanta Pharmaceuticals position peaked at $22K in Q4 2020.
  • 148 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2021.

Based on Vantage Consulting Group's 13F filing for Q1 2021, filed 14 May 2021.